Araştırma Makalesi
BibTex RIS Kaynak Göster

Decreased CDX2 Expression Adversely Effect On Prognosis Of Patients With Colorectal Cancer

Yıl 2020, Cilt: 47 Sayı: 1, 57 - 65, 17.03.2020
https://doi.org/10.5798/dicletip.706005

Öz

Objective: Since colorectal cancers (CRC) are tumors with heterogeneous biological behavior, prediction of their prognosis remains challenging. Caudal-related homeobox gene 2 (CDX2), which has important roles in the development and maintenance of intestines, is thought to have tumor suppressing effect on CRCs. The aim of this study was to investigate the prognostic significance of decreased-CDX2 expression.
Method: This retrospective study included 224 patients diagnosed with CRC between 2009 and 2014. Paraffinized blocks of these patients were stained with CDX2 immunohistochemically and evaluated semiquantitatively.
Results: Only 35 (15.6%) of 224 patients had low-CDX2 expression. Decrease in CDX2 expression was closely associated with classical prognostic parameters such as histopathologic type, histologic grade, lymph node metastasis, distant metastasis, and TNM stage. Patients with decreased-CDX2 expression had more lymph node metastasis (p=0.013) and advanced TNM stage (p=0.004) than those without decreased-expression. The mean survival was 53.0±0.89 months. Cox regression analysis showed that decreased-CDX2 expression was significantly related with overall survival (Univariate analysis; hazard ratio: 0.09, 95% confidence interval: 0.05-0.16; p<0.001; Multivariate analysis; hazard ratio: 0.24, 95% confidence interval: 0.13-0.48; p<0.001) and disease-free survival (Univariate analysis; hazard ratio: 0.80, 95% confidence interval: 0.05-0.13; p<0.001; Multivariate analysis; hazard ratio: 0.15, 95% confidence interval: 0.08-0.25; p<0.001).
Conclusion: Decreased CDX2 expression is significantly related with worse biological features and can be used as an independent prognostic biomarker in patients with CRCs.

Kaynakça

  • 1. Haddad FG, Eid R, Kourie HR, Barouky E, Ghosn M. Prognostic and predictive biomarkers in nonmetastatic colorectal cancers. Future Oncol 2018; 14: 2097-102.
  • 2. Akdeniz N, Kaplan MA, Küçüköner M, et al. Prognostic importance of primary tumor location in RAS mutant metastatic colorectal cancer. Dicle Med J 2019; 46: 247-53.
  • 3. Slik K, Turkki R, Carpén O, et al. CDX2 Loss With Microsatellite Stable Phenotype Predicts Poor Clinical Outcome in Stage II Colorectal Carcinoma. Am J SurgPathol 2019; 43: 1473-82.
  • 4. Xiong Y, You W, Hou M, et al. Nomogram Integrating Genomics with Clinicopathologic Features Improves Prognosis Prediction for Colorectal Cancer. Mol Cancer Res 2018; 16: 1373-84.
  • 5. Shigematsu Y, Inamura K, Yamamoto N, et al. Impact of CDX2 expression status on the survival of patients after curative resection for colorectal cancer liver metastasis. BMC Cancer 2018; 18: 980.
  • 6. Shigematsu Y, Inamura K, Mise Y, et al. CDX2 expression is concordant between primary colorectal cancer lesions and corresponding liver metastases independent of chemotherapy: a single-center retrospective study in Japan. Oncotarget 2018; 9: 17056-65.
  • 7. Bae JM, Lee TH, Cho NY, Kim TY, Kang GH. Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients. World J Gastroenterol 2015; 21: 1457-67.
  • 8. Kaimaktchiev V, Terracciano L, Tornillo L, et al. The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod Pathol 2004; 17: 1392-99.
  • 9. Hryniuk A, Grainger S, Savory JG, Lohnes D. Cdx1 and Cdx2 function as tumor suppressors. J BiolChem 2014; 289: 33343-54.
  • 10. Matsuda M, Sentani K, Noguchi T, et al. Immunohistochemical analysis of colorectal cancer with gastric phenotype: claudin-18 is associated with poor prognosis. PatholInt 2010; 60: 673-80. 11. Xu W, Zhu Y, Shen W, et al. Combination of CDX2 expression and T stage improves prognostic prediction of colorectal cancer. J Int Med Res 2019; 47: 1829-42.
  • 12. Hong KD, Lee D, Lee Y, Lee SI, Moon HY. Reduced CDX2 expression predicts poor overall survival in patients with colorectal cancer. Am Surg 2013; 79: 353-60.
  • 13. Hari DM, Leung AM, Lee JH, et al. AJCC Cancer Staging Manual 7th edition criteria for colon cancer: do the complex modifications improve prognostic assessment? J Am CollSurg 2013; 217: 181-90.
  • 14. Dalerba P, Sahoo D, Paik S, et al. CDX2 as a prognostic biomarker in stage II and stage III colon cancer. N Engl J Med 2016; 374: 211–22.
  • 15. Olsen J, Espersen ML, Jess P, Kirkeby LT, Troelsen JT. The clinical perspectives of CDX2 expression in colorectal cancer: a qualitative systematic review. SurgOncol 2014; 23: 167-76.
  • 16. Hansen TF, Kjaer-Frifeldt S, Eriksen AC, et al. Prognostic impact of CDX2 in stage II colon cancer: results from two nationwide cohorts. Br J Cancer 2018; 119: 1367-73.
  • 17. Lugli A, Tzankov A, Zlobec I, Terracciano LM. Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status. Mod Pathol 2008; 21: 1403-12.
  • 18. Tóth C, Sükösd F, Valicsek E, et al. Loss of CDX2 gene expression is associated with DNA repair proteins and is a crucial member of the Wnt signaling pathway in liver metastasis of colorectal cancer. Oncol Lett 2018; 15: 3586-93.
  • 19. Misiakos EP, Karidis NP and Kouraklis G: Current treatment for colorectal liver metastases. World J Gastroenterol 2011; 17: 4067-75.
  • 20. Baba Y, Nosho K, Shima K, et al. Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer. Clin Cancer Res 2009; 15: 4665-73.
  • 21. Dawson H, Galván JA, Helbling M, et al. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency. Int J Cancer 2014; 134: 2342-51.
  • 22. Dawson H, Koelzer VH, Lukesch AC, et al. Loss of Cdx2 Expression in Primary Tumors and Lymph Node Metastases is Specific for Mismatch RepairDeficiency in Colorectal Cancer. Front Oncol 2013; 3: 265.

Ayrıntılar

Birincil Dil İngilizce
Konular Sağlık Kurumları Yönetimi
Bölüm Original Articles
Yazarlar

İlknur ÇALIK Bu kişi benim

Muhammet ÇALIK Bu kişi benim

İbrahim Hanifi ÖZERCAN Bu kişi benim

Adile Ferda DAĞLI Bu kişi benim

Gökhan ARTAŞ Bu kişi benim

Gülistan TÜRKEN Bu kişi benim

Burcu SARIKAYA Bu kişi benim

Yayımlanma Tarihi 17 Mart 2020
Gönderilme Tarihi 19 Ekim 2019
Yayımlandığı Sayı Yıl 2020 Cilt: 47 Sayı: 1

Kaynak Göster

APA ÇALIK, İ., ÇALIK, M., ÖZERCAN, İ. H., DAĞLI, A. F., vd. (2020). Decreased CDX2 Expression Adversely Effect On Prognosis Of Patients With Colorectal Cancer. Dicle Tıp Dergisi, 47(1), 57-65. https://doi.org/10.5798/dicletip.706005
AMA ÇALIK İ, ÇALIK M, ÖZERCAN İH, DAĞLI AF, ARTAŞ G, TÜRKEN G, SARIKAYA B. Decreased CDX2 Expression Adversely Effect On Prognosis Of Patients With Colorectal Cancer. diclemedj. Mart 2020;47(1):57-65. doi:10.5798/dicletip.706005
Chicago ÇALIK, İlknur, Muhammet ÇALIK, İbrahim Hanifi ÖZERCAN, Adile Ferda DAĞLI, Gökhan ARTAŞ, Gülistan TÜRKEN, ve Burcu SARIKAYA. “Decreased CDX2 Expression Adversely Effect On Prognosis Of Patients With Colorectal Cancer”. Dicle Tıp Dergisi 47, sy. 1 (Mart 2020): 57-65. https://doi.org/10.5798/dicletip.706005.
EndNote ÇALIK İ, ÇALIK M, ÖZERCAN İH, DAĞLI AF, ARTAŞ G, TÜRKEN G, SARIKAYA B (01 Mart 2020) Decreased CDX2 Expression Adversely Effect On Prognosis Of Patients With Colorectal Cancer. Dicle Tıp Dergisi 47 1 57–65.
IEEE İ. ÇALIK, “Decreased CDX2 Expression Adversely Effect On Prognosis Of Patients With Colorectal Cancer”, diclemedj, c. 47, sy. 1, ss. 57–65, 2020, doi: 10.5798/dicletip.706005.
ISNAD ÇALIK, İlknur vd. “Decreased CDX2 Expression Adversely Effect On Prognosis Of Patients With Colorectal Cancer”. Dicle Tıp Dergisi 47/1 (Mart 2020), 57-65. https://doi.org/10.5798/dicletip.706005.
JAMA ÇALIK İ, ÇALIK M, ÖZERCAN İH, DAĞLI AF, ARTAŞ G, TÜRKEN G, SARIKAYA B. Decreased CDX2 Expression Adversely Effect On Prognosis Of Patients With Colorectal Cancer. diclemedj. 2020;47:57–65.
MLA ÇALIK, İlknur vd. “Decreased CDX2 Expression Adversely Effect On Prognosis Of Patients With Colorectal Cancer”. Dicle Tıp Dergisi, c. 47, sy. 1, 2020, ss. 57-65, doi:10.5798/dicletip.706005.
Vancouver ÇALIK İ, ÇALIK M, ÖZERCAN İH, DAĞLI AF, ARTAŞ G, TÜRKEN G, SARIKAYA B. Decreased CDX2 Expression Adversely Effect On Prognosis Of Patients With Colorectal Cancer. diclemedj. 2020;47(1):57-65.